相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study
M. Nauck et al.
DIABETES OBESITY & METABOLISM (2013)
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
John B. Buse et al.
LANCET (2013)
Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction
Sheldon Russell
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY (2013)
Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes
Adrian S. Dobs et al.
JOURNAL OF DIABETES (2013)
The effects of sitagliptin on gastric emptying in healthy humans - a randomised, controlled study
J. E. Stevens et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review
Vanita R. Aroda et al.
CLINICAL THERAPEUTICS (2012)
Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin
Anthony H. Barnett et al.
CURRENT MEDICAL RESEARCH AND OPINION (2012)
Safety and Efficacy of Once-Weekly Exenatide Compared With Insulin Glargine Titrated to Target in Patients With Type 2 Diabetes Over 84 Weeks
Michaela Diamant et al.
DIABETES CARE (2012)
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Silvio E. Inzucchi et al.
DIABETES CARE (2012)
Mechanisms for the Antihyperglycemic Effect of Sitagliptin in Patients with Type 2 Diabetes
Elza Muscelli et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial
Pablo Aschner et al.
LANCET (2012)
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
Baptist Gallwitz et al.
LANCET (2012)
Use of Twice-Daily Exenatide in Basal Insulin-Treated Patients With Type 2 Diabetes A Randomized, Controlled Trial
John B. Buse et al.
ANNALS OF INTERNAL MEDICINE (2011)
Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual β-Cell Function
Urd Kielgast et al.
DIABETES (2011)
Gastric Bypass Surgery Enhances Glucagon-Like Peptide 1-Stimulated Postprandial Insulin Secretion in Humans
Marzieh Salehi et al.
DIABETES (2011)
Weight-Related Quality of Life, Health Utility, Psychological Well-Being, and Satisfaction With Exenatide Once Weekly Compared With Sitagliptin or Pioglitazone After 26 Weeks of Treatment
Jennie H. Best et al.
DIABETES CARE (2011)
Use of Dipeptidyl Peptidase-4 Inhibitors and the Reporting of Infections: A Disproportionality Analysis in the World Health Organization VigiBase
Marjolein J. Willemen et al.
DIABETES CARE (2011)
Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study
K. Kaku et al.
DIABETES OBESITY & METABOLISM (2011)
Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial
S. Del Prato et al.
DIABETES OBESITY & METABOLISM (2011)
Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study
D. R. Owens et al.
DIABETIC MEDICINE (2011)
Pharmacology of Dipeptidyl Peptidase-4 Inhibitors Similarities and Differences
Roberta Baetta et al.
DRUGS (2011)
Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1-Based Therapies
Michael Elashoff et al.
GASTROENTEROLOGY (2011)
Endogenous GLP-1 Regulates Postprandial Glycemia in Humans: Relative Contributions of Insulin, Glucagon, and Gastric Emptying
Mathias Nicolaus et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes
Thomas Blevins et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Differential Effect of Sham Feeding on Meal Glucose Tolerance in Hypoglycemic vs. Asymptomatic Individuals after Gastric Bypass Surgery
Marzieh Salehi et al.
DIABETES (2011)
Effect of Endogenous GLP-1 on Insulin Secretion in Type 2 Diabetes
Marzieh Salehi et al.
DIABETES (2010)
Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin
Rajesh Garg et al.
DIABETES CARE (2010)
Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes
D. Williams-Herman et al.
DIABETES OBESITY & METABOLISM (2010)
Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes
P. Aschner et al.
DIABETES OBESITY & METABOLISM (2010)
An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials
M. Ligueros-Saylan et al.
DIABETES OBESITY & METABOLISM (2010)
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
T. Vilsboll et al.
DIABETES OBESITY & METABOLISM (2010)
Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus
Andre J. Scheen et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2010)
Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation
Lotte Bjerre Knudsen et al.
ENDOCRINOLOGY (2010)
Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time
B. Gallwitz et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2010)
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
Michaela Diamant et al.
LANCET (2010)
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
Richard M. Bergenstal et al.
LANCET (2010)
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
Richard E. Pratley et al.
LANCET (2010)
Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
Debora Williams-Herman et al.
BMC ENDOCRINE DISORDERS (2010)
Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes
J. Rosenstock et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
Michael Nauck et al.
DIABETES CARE (2009)
Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
Bernard Zinman et al.
DIABETES CARE (2009)
The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone
Ralph A. DeFronzo et al.
DIABETES CARE (2009)
Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes A retrospective cohort study
Rebecca A. Noel et al.
DIABETES CARE (2009)
Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycaemia
J. Rosenstock et al.
DIABETES OBESITY & METABOLISM (2009)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy
R. E. Pratley et al.
DIABETES OBESITY & METABOLISM (2009)
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
M. Marre et al.
DIABETIC MEDICINE (2009)
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
D. Russell-Jones et al.
DIABETOLOGIA (2009)
Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study
M. A. Nauck et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2009)
Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial
A. R. Chacra et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2009)
Saxagliptin Added to a Thiazolidinedione Improves Glycemic Control in Patients with Type 2 Diabetes and Inadequate Control on Thiazolidinedione Alone
Priscilla Hollander et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
Alan Garber et al.
LANCET (2009)
Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
Arne Astrup et al.
LANCET (2009)
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
John B. Buse et al.
LANCET (2009)
Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptino: A randomized, double-mind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes
Paul Covington et al.
CLINICAL THERAPEUTICS (2008)
Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control A randomized, double-blind, placebo-controlled study
Ralph A. DeFronzo et al.
DIABETES CARE (2008)
Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy
B. Schwarz et al.
DIABETES OBESITY & METABOLISM (2008)
Regulation of Islet Hormone Release and Gastric Emptying by Endogenous Glucagon-Like Peptide 1 after Glucose Ingestion
Marzieh Salehi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
Daniel J. Drucker et al.
LANCET (2008)
Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients
Elza Muscelli et al.
DIABETES (2008)
Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats
Torsten P. Vahl et al.
ENDOCRINOLOGY (2007)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin
K. Hermansen et al.
DIABETES OBESITY & METABOLISM (2007)
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes
Barry J. Goldstein et al.
DIABETES CARE (2007)
Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor
Arthur J. Bergman et al.
DIABETES CARE (2007)
Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes
Dennis Kim et al.
DIABETES CARE (2007)
Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes
Adrian Vella et al.
DIABETES (2007)
The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes - A randomized trial
Bernard Zinman et al.
ANNALS OF INTERNAL MEDICINE (2007)
Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes - A 24-week, double-blind, randomized trial
Julio Rosenstock et al.
DIABETES CARE (2007)
A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study
M. A. Nauck et al.
DIABETOLOGIA (2007)
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials
John B. Buse et al.
CLINICAL THERAPEUTICS (2007)
Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes
Tina Vilsboll et al.
DIABETES CARE (2007)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial
M. A. Nauck et al.
DIABETES OBESITY & METABOLISM (2007)
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Steven E. Kahn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes
Pablo Aschner et al.
DIABETES CARE (2006)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
Bernard Charbonnel et al.
DIABETES CARE (2006)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus
I. Raz et al.
DIABETOLOGIA (2006)
Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans
J Schirra et al.
GUT (2006)
Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers
AJ Bergman et al.
CLINICAL THERAPEUTICS (2006)
Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes
F Fehse et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes - A randomized trial
RJ Heine et al.
ANNALS OF INTERNAL MEDICINE (2005)
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
DM Kendall et al.
DIABETES CARE (2005)
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
RA DeFronzo et al.
DIABETES CARE (2005)
Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion
LA Nikolaidis et al.
CIRCULATION (2004)
Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes
JJ Meier et al.
CRITICAL CARE MEDICINE (2004)
Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes
LL Nielsen et al.
REGULATORY PEPTIDES (2004)
Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells
A Nakagawa et al.
AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL (2004)
Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia
KB Degn et al.
DIABETES (2004)
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
JB Buse et al.
DIABETES CARE (2004)
Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets
L Farilla et al.
ENDOCRINOLOGY (2003)
Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect
RL Prigeon et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2003)
Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects
T Vilsboll et al.
REGULATORY PEPTIDES (2003)
Synthetic exendin-4 (Exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes
OG Kolterman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes
JJ Meier et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1-(9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans
TP Vahl et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy
DD De León et al.
DIABETES (2003)
Glucagon-like peptide-1 receptor signaling modulates β cell apoptosis
YZ Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats
L Farilla et al.
ENDOCRINOLOGY (2002)
Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells
EJ Abraham et al.
ENDOCRINOLOGY (2002)
Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers
MA Nauck et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor
R Burcelin et al.
DIABETES (2001)
Impaired glucose tolerance and dyslipidaemia as late effects after bone-marrow transplantation in childhood
M Taskinen et al.
LANCET (2000)
Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration
LB Knudsen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)